<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784860</url>
  </required_header>
  <id_info>
    <org_study_id>LIDOCOLO2016JJCF</org_study_id>
    <nct_id>NCT02784860</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Lidocaine During Sedation for Colonoscopy.</brief_title>
  <official_title>Investigation of the Effects of Intravenous Lidocaine Infusion During Sedation for Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the benefits of continuous intravenous lidocaine administration during
      sedation for colonoscopy.

      Sedation will consist of propofol infusion titrated to provide adequate working conditions to
      the gastroenterologist. Patients will be randomly allocated into two groups: lidocaine
      infusion (bolus of 1.5 mg/kg followed by a continuous infusion of 4 mg/kg/h) or the same
      volume of placebo (normal saline)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The potential benefits of lidocaine infusion will be tested on:

        -  propofol consumption (primary outcome)

        -  intraoperative respiratory depression

        -  time for patient recovery

        -  postoperative fatigue

        -  postoperative pain

        -  postoperative cognitive dysfunction
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Consumption of propofol</measure>
    <time_frame>intraoperative</time_frame>
    <description>Dose of propofol administered during sedation if measured at the end of it.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Episodes of oxygen desaturation</measure>
    <time_frame>intraoperative</time_frame>
    <description>Episodes of oxygen desaturation: SpO2 &lt; 95 and 90%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for recovery</measure>
    <time_frame>intraoperative</time_frame>
    <description>the patient is discharged when conscious and able to give his birth date</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of working conditions assessed by the gastroenterologist</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal discomfort</measure>
    <time_frame>intraoperative and 15 minutes later</time_frame>
    <description>Evaluation with VAS (visual analog scale) form 0 (no discomfort) to 10 (unbearable Abdominal discomfort assessed on a 0 to 10 visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative fatigue</measure>
    <time_frame>15 min after sedation</time_frame>
    <description>Fatigue will be assessed on a visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive condition</measure>
    <time_frame>15 minutes after sedation</time_frame>
    <description>Cognitive condition will be evaluated with the MMSE (Minimal Mental State Examination)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lidocaine. Administration of lidocaine is started with 1.5 mg/kg bolus injection followed by a continuous infusion of 4mg/kg/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Administration of normal saline: same volume of saline as lidocaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness</description>
    <arm_group_label>Lidocaine</arm_group_label>
    <other_name>XYLOCAINE ; (NDA) 006488</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  colonoscopy without gastroscopy

        Exclusion Criteria:

          -  lidocaine allergy

          -  epilepsy

          -  severe heart rhythm disorders

          -  renal failure with creatinine clearance lower than 30ml/minute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Joris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Liege</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2016</study_first_submitted>
  <study_first_submitted_qc>May 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2016</study_first_posted>
  <last_update_submitted>December 29, 2017</last_update_submitted>
  <last_update_submitted_qc>December 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Jean Fran√ßois Brichant</investigator_full_name>
    <investigator_title>Professor and Chair</investigator_title>
  </responsible_party>
  <keyword>colonoscopy</keyword>
  <keyword>lidocaine</keyword>
  <keyword>propofol</keyword>
  <keyword>sedation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

